---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040318"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:49:04.617009+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Abeona submits BLA for pz-cel; Q3 net loss $11.8M, cash $54.1M

## Summary
- Q3 net loss $11.8M ($0.48/share) vs $6.4M ($1.00/share) in Q3 2022.
- Cash and short-term investments $54.1M; estimated runway into Q4 2024.
- BLA for pz-cel (gene therapy for RDEB) submitted in September; FDA decision expected late-Nov 2023.
- Raised $25M in July registered direct offering; commercial launch prep underway.
- Appointed Madhav Vasanthavada as Chief Commercial Officer.

## SEC filing metadata
- accession: 0001493152-23-040318
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315223040318/0001493152-23-040318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315223040318/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040318
- JSON: https://secwatch.observer/filing/0001493152-23-040318.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040318.txt

## Key facts
- Earnings Releases
  ABEONA THERAPEUTICS INC. reported the third quarter of 2023 results: net income Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common s, EPS $0.48 loss per common share.
  - Period: the third quarter of 2023
  - Net income: Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common s
  - EPS: $0.48 loss per common share
  - Result: reported results
  source text: Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common share as compared to a net loss attributable to common shareholders of $6.4 million, or $1.00 loss per common share, in the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315223040318/0001493152-23-040318-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.